Induced humoral immunity and vaccination against major human fungal pathogens

Current Opinion in Microbiology

Volumn 5, Issue 4, 2002, Pages 386-391

  Casadevall, Arturo ^a   Feldmesser, Marta ^a   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGUS VACCINE; GLUCURONOXYLOMANNAN TETANUS TOXOID CONJUGATE VACCINE; MONOCLONAL ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CELLULAR IMMUNITY; CRYPTOCOCCUS NEOFORMANS; FUNGUS; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNITY; NONHUMAN; REVIEW; VACCINATION;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA ALBICANS; FILOBASIDIELLA NEOFORMANS; FUNGI;

EID: 0036345760     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(02)00337-5     Document Type: Review

References (72)

1. The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections
2. Prospects for the development of fungal vaccines
3. Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans
4. The Cryptococcus neoformans gene DHA1 encodes an antigen that elicits a delayed-type hypersensitivity reaction in immune mice
5. Protective efficacy of H antigen from Histoplasma capsulatum in a murine model of pulmonary histoplasmosis
6. Immunogenicity and protective efficacy of the WI-1 adhesin of Blastomyces dermatitidis
7. Recombinant urease and urease DNA of Coccidioides immitis elicit an immunoprotective response against coccidioidomycosis in mice
8. Evaluation of the proline-rich antigen of Coccidioides immitis as a vaccine candidate in mice
9. Primary role for CD4(+) T lymphocytes in recovery from oropharyngeal candidiasis
10. Serologic evidence for Cryptococcus infection in early childhood
11. Role of antibodies and effect of BCG vaccination in experimental candidiasis in mice
12. B cell knockout mice are resistant to mucosal and systemic candidiasis of endogenous origin but susceptible to experimental systemic candidiasis
13. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy
14. Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans
15. Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans
16. Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans
17. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection
18. Candida albicans mannan extractprotein conjugates induce a protective immune response against experimental candidiasis
19. Antibody response that protects against disseminated candidiasis
20. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody
21. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies
22. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis
23. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals
24. Antifungal antibodies: A new approach to the treatment of systemic candidiasis
25. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal infection
26. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats
27. Effective phagocytosis and killing of Candida albicans via targeting FcγRI (CD64) or FcαRI (CD89) on neutrophils
28. Therapeutic potential of antildiotypic single chain antibodies with yeast killer toxin activity
29. Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria
30. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens
31. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis
32. Antifungal activity of a human antiglucuronoxylomannan antibody
33. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody
34. Passive immunization against Cryptococcus neoformans with an isotypeswitch family of monoclonal antibodies reactive with cryptococcal polysaccharide
35. Protective murine monoclonal antibodies to Cryptococcus neoformans
36. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis
37. Characterization of a murine monoclonal antibody to Cryptocococcus neoformans polysaccharide that is a candidate for human therapeutic studies
38. Isotype switching increases antibody protective efficacy to Cryptococcus neoformans infection in mice
39. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy
40. Immunoglobulin M efficacy against Cryptococcus neoformans: Mechanism, dose dependence and prozone-like effects in passive protection experiments
41. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice
42. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans
43. Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with subtle pleotrophic effects on the cytokine and leukocyte response
44. Effect of serum IgG1 against murine pulmonary infection with Cryptococcus neoformans
45. Experimental murine cryptococcosis: Effect of hyperimmunization to capsular polysaccharide
46. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model
47. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection
48. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide
49. Molecular basis for Immunoglobulin M specificity to epitopes in Cryptococcus neoformans that elicit protective and non-protective antibodies
50. Use of recombinant mitogillin for improved serodiagnosis of Aspergillus fumigatus-associated diseases
51. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus
52. Interaction of Aspergillus fumigatus spores and pulmonary alveolar macrophages of rabbits
53. Experimental avian aspergillosis
54. Acquired immunity in experimental murine aspergillosis is mediated by macrophages
55. T cell vaccination in mice with invasive pulmonary aspergillosis
56. Immunologic studies of disseminated infection with Aspergillus fumigatus in the nude mouse
57. The effect of elastasespecific monoclonal and polyclonal antibodies on the virulence of Aspergillus fumigatus in immunocompromised mice
58. An endotoxin from Aspergillus fumigatus
59. Vaccination studies of aspergillosis in turkeys: Subcutaneous inoculation with several vaccine preparations followed by aerosol challenge exposure
60. Value of antigen and antibody detection, and blood evaluation parameters in diagnosis of avian invasive aspergillosis
61. Aspergillus fumigatus and aspergillosis
62. Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans
63. Antibody-mediated effects against Cryptococcus neoformans: Evidence for interdependency and collaboration between humoral and cellular immunity
64. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes
65. Antibody immunity and invasive fungal infections
66. Immunoglobulin G3 blocking antibodies to Cryptococcus neoformans
67. Cutting edge: Paradigm revisited: Antibody provides resistance to Listeria infection
68. A monoclonal antibody recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival
69. Generation of monoclonal antibodies to Histoplasma capsulatum and their effect on murine infection
70. Investigation of anti-WI-I adhesin antibodymediated protection in experimental pulmonary blastomycoses
71. Immunogenicity and safety of a conjugate glucuronoxylomannantetanus conjugate vaccine in volunteers